Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
Clinical trial NCT01282268 · COMPLETED
Trial details
- NCT number
- NCT01282268
- Sponsor
- Seaside Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2011-05-01
- Primary completion
- 2012-12-01
- Enrollment
- 125
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.